Related Experiment Video

Updated: Jul 2, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth

Yvonne G Lin1, Anand Immaneni, William M Merritt

  • 1Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 4, 2008
PubMed
Abstract

Insights

Inhibiting Aurora kinase with MK-0457 significantly reduced ovarian cancer growth and increased apoptosis. Combining MK-0457 with docetaxel enhanced therapeutic efficacy in preclinical models.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Aurora kinases are crucial for maintaining mitotic integrity and regulating the cell cycle.
  • Dysregulation of Aurora kinases is implicated in various cancers, including ovarian cancer.
  • Targeting Aurora kinases presents a potential therapeutic strategy for ovarian cancer.

Purpose of the Study:

  • To investigate the effects of inhibiting Aurora kinase on ovarian cancer progression.
  • To evaluate the efficacy of a small molecule pan-Aurora kinase inhibitor, MK-0457, in an orthotopic ovarian cancer mouse model.
  • To assess the combined therapeutic potential of MK-0457 and docetaxel in ovarian cancer.

Main Methods:

  • In vitro and in vivo ovarian cancer models were utilized.
  • Cell cycle regulatory effects of Aurora kinase inhibition were examined.
  • Therapeutic efficacy of MK-0457, alone and in combination with docetaxel, was assessed in chemo-sensitive and chemo-resistant models.

Main Results:

  • MK-0457 significantly reduced tumor burden, cell proliferation, and increased apoptosis in ovarian cancer models.
  • Combination therapy with MK-0457 and docetaxel demonstrated superior efficacy compared to docetaxel alone.
  • MK-0457 enhanced docetaxel-induced cytotoxicity in vitro and improved tumor growth reduction in vivo.

Conclusions:

  • Aurora kinase inhibition is a promising strategy for reducing ovarian cancer burden and proliferation.
  • Combination therapy with Aurora kinase inhibitors and chemotherapy warrants further clinical investigation.
  • Targeting Aurora kinase activity holds potential for improving ovarian cancer treatment outcomes.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...